Pediatric Praziquantel Consortium

Consortium featured in 1st JAGntd newsletter

09 July 2019

The Pediatric Praziquantel Consortium was featured in the first issue of the Japan Alliance on Global Neglected...

Taking the next step towards access with continued support from the GHIT Fund

09 May 2019

The fourth research grant from the Global Health Innovative Technology (GHIT) Fund provides further support for the...

A new formulation to fight Schistosomiasis

A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more